Evidence map›Paper›PMID 35489179›Full record

ArticleDrug and alcohol dependence2022

Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis.

Ria Garg, Sophie A Kitchen, Siyu Men, Tonya J Campbell, Nikki Bozinoff, Mina Tadrous, Tony Antoniou, Jennifer Wyman, Dan Werb, Charlotte Munro and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug and alcohol dependence, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Impact of COVID-19 Pandemic on Adherence to Chronic Therapies: A Systematic Review.International journal of environmental research and public health · 2023
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

Ria GargFaculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada.
Sophie A KitchenInstitute for Clinical Evaluative Sciences, 2075 Bayview Ave, Toronto, Ontario M4N 3M5, Canada.
Siyu MenInstitute for Clinical Evaluative Sciences, 2075 Bayview Ave, Toronto, Ontario M4N 3M5, Canada.
Tonya J CampbellLi Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond St, Toronto, Ontario M5B 1W8, Canada.
Nikki BozinoffCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario M5T 1R8, Canada; Department of Family and Community Medicine, University of Toronto, 500 University Ave, Toronto, Ontario M5G 1V7, Canada.
Mina TadrousInstitute for Clinical Evaluative Sciences, 2075 Bayview Ave, Toronto, Ontario M4N 3M5, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, Ontario M5S 3M2, Canada; Women's College Hospital, 76 Grenville St, Toronto, Ontario M5S 1B2, Canada.
Tony AntoniouInstitute for Clinical Evaluative Sciences, 2075 Bayview Ave, Toronto, Ontario M4N 3M5, Canada; Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond St, Toronto, Ontario M5B 1W8, Canada; Department of Family and Community Medicine, University of Toronto, 500 University Ave, Toronto, Ontario M5G 1V7, Canada; Department of Family and Community Medicine, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada.
Jennifer WymanLeslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, Ontario M5S 3M2, Canada; Women's College Hospital, 76 Grenville St, Toronto, Ontario M5S 1B2, Canada.
Dan WerbLi Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond St, Toronto, Ontario M5B 1W8, Canada; Department of Family and Community Medicine, St. Michael's Hospital, 30 Bond Street, Toronto, Ontario M5B 1W8, Canada; Division of Infectious Diseases & Global Public Health at the University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA.
Charlotte MunroOntario Drug Policy Research Network Lived Experience Advisory Group, Canada.
Tara GomesInstitute for Clinical Evaluative Sciences, 2075 Bayview Ave, Toronto, Ontario M4N 3M5, Canada; Li Ka Shing Knowledge Institute of St. Michael's Hospital, 30 Bond St, Toronto, Ontario M5B 1W8, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College St, Toronto, Ontario M5S 3M2, Canada; Institute of Health Policy, Management & Evaluation at the University of Toronto, 155 College St, Toronto, Ontario M5T 3M6, Canada. Electronic address: tara.gomes@unityhealth.to.
University of Toronto · CAInstitute for Clinical Evaluative Sciences · CASt. Michael's Hospital · CACentre for Addiction and Mental Health · CAOntario Drug Policy Research Network · CAUniversity of British Columbia · CAWomen's College Hospital · CA

Funding

CIHR 153070
6 · The paper itself

Abstract

backgroundWe assessed the impact of COVID-19, which includes the declaration of a state of emergency and subsequent release of pandemic-specific OAT guidance (March 17, 2020 to March 23, 2020) on the prevalence of OAT discontinuation.

methodsWe conducted a population-based time series analysis using interventional autoregressive integrated moving average models among Ontario residents who were stable (>60 days of continuous use) and not yet stable on OAT. Specifically, we examined whether COVID-19 impacted the weekly percentage of individuals who discontinued OAT, overall and stratified by treatment type (methadone vs. buprenorphine/naloxone). Additionally, we compared demographic characteristics and patient outcomes among people stable on OAT who discontinued treatment during (March 17, 2020 to November 30, 2020) and prior (July 3, 2019 to March 16, 2020) to the pandemic.

resultsThe weekly prevalence of OAT discontinuation across the study period ranged between 0.6% and 1.1%, among those stable on treatment compared to 7.3% and 16.6%, among those not stable on treatment. Following COVID-19, there was no significant change in the percentage of Ontarians who discontinued OAT, regardless of whether they were stabilized on treatment. Among those stable on OAT, a similar proportion of patients restarted therapy and experienced opioid-related harm following an OAT discontinuation. However, mortality following OAT discontinuation must be noted, as approximately 1.4% and 0.8% of people who discontinued methadone and buprenorphine/naloxone respectively, died within 30 days of discontinuation.

conclusionsTrends in the prevalence of OAT discontinuation did not significantly change during the first eight months of the COVID-19 pandemic.

Indexed as

BuprenorphineCOVID-19Opioid-Related DisordersAnalgesics, OpioidBuprenorphine, Naloxone Drug CombinationHumansMethadoneOntarioOpiate Substitution TreatmentPandemicsPrevalenceTime FactorsAnalgesics, OpioidBuprenorphineBuprenorphine, Naloxone Drug CombinationMethadoneAdherenceCOVID-19Opioid agonist therapy

Identifiers

PMID35489179
PMCPMC9008980
OpenAlexW4225279871

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.